EMBioSys receives a SBIR Phase 1 Award from the National Cancer Institute!

Written By Chris Barron

EMBioSys is excited to announce that we have received a Small Business Innovation Research (SBIR) Phase 1 Award from the National Cancer Institute for Development of a Wearable, Non-invasive, Treatment Device for Metastatic Triple-Negative Breast Cancer (TNBC). We are grateful to the NIH/NCI in recognizing the potential of our therapeutic induced electric field (iEF) technology towards improving treatment outcomes and potentiating standard of care for treatment of solid metastatic cancers.

We look forward to collaborating with our research partners at The Ohio State University on this award.

Chris Barron
Previous

Silvia C. Formenti, MD has joined our Advisory Board!
Next

EMBioSys Welcomes Dr. Joe Camardo as Medical Advisor!